Lycia Therapeutics Inc, established in 2019, is a biotechnology company using its lysosomal targeting chimeras (LYTACs) platform to discover and develop first-in-class therapeutics that degrade extracellular and membrane-bound proteins that drive a range of difficult-to-treat diseases, including cancers and autoimmune conditions.In September 2021, Lycia Therapeutics Inc completed oversubscribed $70 million Series B financing round